A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease

R

Renibus Therapeutics

Status and phase

Completed
Phase 1

Conditions

Kidney Failure, Acute

Treatments

Drug: RBT-3

Study type

Interventional

Funder types

Industry

Identifiers

NCT04072432
REN-002

Details and patient eligibility

About

This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.

Enrollment

18 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male and female subjects age 18 to 80 years (inclusive, at time of ICF).
  • Body weight <125 kg.
  • Able and willing to comply with all study procedures.

Female subjects must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 8 days after study drug administration.

Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 8 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.

CKD as determined by estimated glomerular filtration rate (eGFR) between 15-59 ml/min as estimated using the CKD-EPI equation (CKD class 3-4).

Exclusion criteria

  • History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers.
  • Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer.
  • Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening.
  • Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
  • Any significant acute or chronic diseases, excluding CKD (eGFR ≥15 ml/min).
  • Regular use of drugs of abuse and/or positive findings on urinary drug screening.
  • Current tobacco use and/or positive findings on urinary cotinine screening.
  • Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.
  • Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
  • Known hypersensitivity or previous anaphylaxis to FeS.

Trial design

18 participants in 3 patient groups

Cohort 1
Experimental group
Description:
120 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
Treatment:
Drug: RBT-3
Cohort 2
Experimental group
Description:
240 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
Treatment:
Drug: RBT-3
Cohort 3
Experimental group
Description:
360 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
Treatment:
Drug: RBT-3

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems